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Abstract
The lung is, more than other solid organs, susceptible for ischemia reperfusion injury after orthotopic transplantation.
Corticosteroids are known to potently suppress pro-inflammatory processes when given in the post-operative setting
or during rejection episodes. Whereas their use has been approved for these clinical indications, there is no study
investigating its potential as a preservation additive in preventing vascular damage already in the phase of ischemia.
To investigate these effects we performed orthotopic lung transplantations (LTX) in the rat. Prednisolone was either
added to the perfusion solution for lung preservation or omitted and rats were followed for 48 hours after LTX.
Prednisolone preconditioning significantly increased survival and diminished reperfusion edema. Hypoxia induced
vasoactive cytokines such as VEGF were reduced. Markers of leukocyte invasiveness like matrix metalloprotease
(MMP)-2, or common pro-inflammatory molecules like the CXCR4 receptor or the chemokine (C-C motif) ligand
(CCL)-2 were downregulated by prednisolone. Neutrophil recruitment to the grafts was only increased in Perfadex
treated lungs. Together with this, prednisolone treated animals displayed significantly reduced lung protein levels of
neutrophil  chemoattractants  like  CINC-1,  CINC-2α/β  and  LIX  and  upregulated  tissue  inhibitor  of  matrix
metalloproteinase  (TIMP)-1.  Interestingly,  lung  macrophage  invasion  was  increased  in  both,  Perfadex  and
prednisolone  treated  grafts,  as  measured  by  MMP-12  or  RM4.  Markers  of  anti-inflammatory  macrophage
transdifferentiation like MRC-1, IL-13, IL-4 and CD163, significantly correlated with prednisolone treatment. These
observations lead to the conclusion that prednisolone as an additive to the perfusion solution protects from hypoxia
triggered danger signals already in the phase of ischemia and thus reduces graft edema in the phase of reperfusion.
Additionally,  prednisolone  preconditioning  might  also  lead  to  macrophage  polarization  as  a  beneficial  long-term
effect.
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INTRODUCTION
Ischemia-reperfusion  (IR)  is  mainly  characterized  by  an
overshooting inflammatory response leading to tissue edema
[1–3] and probably resulting in primary graft dysfunction [4]. It
affects  an  estimated  10  to  25%  of  all  lung  transplants  [5].
Ischemia  reperfusion  injury  is  known  to  prime  transplanted
organs  to  be  more  susceptible  for  later  rejection  episodes
[6–8]. Preventing the occurrence of such reperfusion damages
might be an important therapeutic strategy in conserving the
organ’s long-term function [5].
Although  there  are  many  therapeutic  strategies  for  the
treatment  of  acute  complications,  there  is  no  direct  causal
therapy to prevent IR damage [5]. In a previous work, we could
show  that  a  direct  inhibition  of  the  hypoxia  driven  signaling
pathways might be a beneficial approach to induce ischemia
tolerance  in  organs  and  to  improve  outcome  after
transplantation. In that case we used Deguelin, a substance of
poor  solubility  and  poor  tolerability  at  high  doses,  to  inhibit
hypoxia inducible factor (HIF) mediated inflammation. The main
mode  of  action  of  Deguelin  consists  in  the  prevention  of
pulmonary edema formation by indirectly inhibiting the vascular
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times more potent in its pro-edematous action than histamine
[4,9]. In our search for a better substance, prednisolone came
into our focus. Glucocorticoids are well-characterized and well
tolerable  substances  that  play  an  important  role  in
transplantation medicine.
Glucocorticoids have a broad mode of action by interfering
with  pro  inflammatory  gene  expression  mainly  via  nuclear
factor (NF) κB Inhibition [10,11]. This mechanism leads to the
suppression or modulation of many pro-inflammatory pathways
and results in the inhibition of the recruitment of inflammatory
cells  into  the  newly  transplanted  organ  [12].  Prednisolone
mainly  inhibits  the  loco-regional  production  of  substances
important  for  airway  inflammation,  namely  interferon  (IFN)-γ,
CXCR4  and  interleukin  (IL)-6  [13–15].  These  proteins  are
largely  responsible  for  early  graft  inflammation  following
ischemia  and  reperfusion,  especially  after  transplantation.
Prednisolone  acts  anti-inflammatory  by  abrogating  their
expression  already  at  a  transcriptional  level.  However,
glucocorticoids not only downregulate pro-inflammatory genes,
but also enhance the production of anti-inflammatory proteins
such as IL-4, IL-13 or IL-10 [16,17].
Reperfusion  injury  is  mainly  mediated  through  cellular
inflammation which is a biphasic process involving a first line of
attack  by  macrophages  and  later  on  by  neutrophils  [18–20].
Macrophages are able to quickly respond to pro-inflammatory
stimuli and chemoattractants produced in alveolar cells during
ischemia.  The  attractants  induce  a  first  line  response  in
resident macrophages, which then potentiate inflammation by
triggering the recruitment of other immune cells like neutrophils
[21–24]. Whereas the classical function of macrophages is the
unspecific removal of substances invading the body, there is
increasing  evidence  that  macrophages  also  modulate  the
inflammatory response. For several years now, the existence of
anti-inflammatory  or  M2  macrophages  has  been  described.
More  interestingly,  with  the  increasing  understanding  of  the
biological  functions  and  interplays  of  the  different  cyto-  and
chemokines, the underlying differentiation pathways from M1 to
M2  macrophages  could  be  elucidated  [25].  Several  gene
products that play an important role in M2 differentiation have
been  described,  such  as  macrophage  mannose  receptor
(MRC)-1,  IL-13,  IL1  receptor  antagonist  (IL1ra)  and  CD163
[26–28].  For  some  diseases  glucocorticoids  have  been
observed to favor M2 polarization by interfering with the latter
pathways [29]. In this complex pathway, IL-4, IL-10 and IL13
occupy a pivotal role. Glucocorticoids induce the production of
IL-4  and  IL-13,  which  in  turn  activate  STAT-6,  a  signaling
pathway  member  that  finally  induces  M2  polarization  by
upregulating  MRC-1  and  CD163.  IL-10  plays  a  rather
differential  role,  some  investigations  describe  IL-10  inducing
macrophage  polarization  by  activating  STAT-3,  which  in  turn
synergizes  with  STAT-6  and  results  in  MRC-1  and  CD-163
upregulation [30–32]. IL-10 has also been described to play a
context  specific  pro-inflammatory  role  that  is  regulated  by
spacio-temporal  factors  [4,33,34].  Regulation  of  these
pathways  is  ensured  by  activation  of  SOCS-1  and  -3,  two
signaling  molecules  that  inhibit  either  STAT-6  or  STAT-3
directly [35–37].
Other important cellular populations that play a crucial role in
the  pathogenesis  of  ischemia  and  reperfusion  injury  are
neutrophils.  Cytokine-induced  neutrophil  chemoattractant
(CINC)-1,  CINC-2α/β  and  lipopolysaccharide-induced  CXC
chemokine (LIX) are potent chemoattractants for this cell type.
Their secretion is stimulated upon ischemia by resident cells
like endothelial cells. Matrix-metalloproteinase (MMP)-2, which
is inhibited by the tissue inhibitor of matrix metalloproteinase
(TIMP)-1,  has  been  shown  to  be  induced  by  the  same
mechanisms  and  to  activate  these  neutrophil  specific
chemoattractants [38]. MMP-2 is needed by the neutrophils to
degrade the extracellular matrix, a process that is crucial for
diapedesis.  MMP-2  thus  correlates  with  the  invasiveness  of
these cells during inflammation [39]. Corticoids are known to be
potent inhibitors of MMPs and thus prevent tissue inflammation
and more specifically remodeling, as is the case in lung fibrosis
[40,41], whereas their action on CINC-1, CINC-2α/β and LIX is
largely unknown.
Usually,  corticoids  are  administered  in  transplantation
medicine  before  antigen  contact  is  restored  to  induce
immunotolerance  immediately  before  restoration  of  the  blood
flow  to  the  transplanted  organ.  However  the  strategy  to  use
prednisolone as an additive to perfusion solutions might have
been  adopted  by  some  transplantation  centers.  To  our
knowledge  there  are  currently  no  experimental  studies
systematically  investigating  the  influence  of  prednisolone  on
ischemia-induced inflammation.
We show that prednisolone not only suppresses reperfusion
damage  by  reducing  hypoxia  induced  signaling,  namely
vascular  endothelial  growth  factor  (VEGF)-A  induced  lung
edema  but  also  induces  transdifferentiation  of  macrophages
towards  an  anti-inflammatory  phenotype,  which  in  turn  may
play a significant role in long-term lung protection.
Results
Prednisolone treatment significantly increases short-
term survival in rats following orthotopic lung
transplantation (LTX)
After  LTX,  animals  were  observed  for  48  hours.  Rats  that
were transplanted with Perfadex-treated lungs had significantly
poorer  short-term  survival  than  the  corresponding  rats
receiving prednisolone pre-conditioned lungs. Mean short-term
survival  was  25.00  ±  10.29  hours  for  Perfadex  only  treated
lungs vs. 43.00 ± 3.52 hours for prednisolone-preconditioned
lungs (p<0.05, Figure 1).
Prednisolone preserves the macro- and microstructural
aspect of the grafts and reduces reperfusion edema
formation following LTX
The explanted lungs from the prednisolone group showed a
better  general  macroscopic  appearance.  Lungs  treated  with
Perfadex only had a dark colored aspect, indicating a higher
fluid content. Prednisolone preconditioned lungs were almost
identical  in  their  macroscopic  aspect  to  lungs  from  sham
animals (Figure 2, A). Moreover, prednisolone preconditioned
lungs  had  a  preserved  alveolar  appearance  and  less
perivascular or cellular edema 48h after reperfusion compared
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edematous  changes,  the  alveolar  wall  thickening  was
quantified  using  an  automatized  algorithm.  Perfadex  treated
lungs  had  significantly  larger  alveoli  whereas  prednisolone-
treated  lungs  were  almost  identical  to  sham  lungs.  By
determining the amount of tissue per picture as described in
the materials and methods section, the cellular swelling can be
calculated. In Perfadex-treated lungs, 88.26 2.54% of the slide
were  covered  by  alveolar  tissue,  whereas  in  prednisolone-
treated lungs only 54.56 2.54% of the slide consisted of lung
tissue (P<0.001*, P<0.01§) (Figure 2, C left graph). For direct
evaluation of the lung water as surrogate for edema, the wet-
to-dry  ratio  was  calculated.  Again,  Perfadex-treated  4.991  ±
0.10 (relative values) lungs had significantly increased tissue
water  than  the  prednisolone  4.549  ±  0.05  (relative  values)
preconditioned  (P<0.05)  and  sham  4.034  ±  0.12  (relative
values)  lungs  (P<0.001).  Although  prednisolone  pretreated
lungs had less edema than Perfadex treated lungs, their water
content  was  significantly  increased  when  compared  to  sham
animals (P<0.01; Figure 2, C right graph).
Prednisolone reduces hypoxia induced signaling and
attenuates VEGF-A expression
Serum concentrations of circulating carbonic anhydrase (CA)
IX  and  VEGF-A  were  determined  as  surrogates  for  hypoxia
induced signaling and reperfusion edema [4]. Circulating CA IX
was  significantly  lower  in  animals  that  received  prednisolone
Figure  1.    Prednisolone  treatment  significantly  increases
short-term  survival  following  orthotopic  lung
transplantation  (LTX).    Mean  short-term  survival  in  hours
following  LTX.  Survival  within  the  observation  period  of  48h
following LTX was tracked. Values are expressed as means ±
standard error of the mean (SEM); significance level was set to
P<0.05,:*,  significantly  different  from  Perfadex-group.
Transplantation procedure was repeated until n=6 survivors per
group  were  obtained  to  ensure  homogenic  comparison
between the groups. ANOVA followed by Bonferroni’s post-hoc
multiple comparisons test.
doi: 10.1371/journal.pone.0073298.g001
100.1 ± 7.9 pg/ml when compared to controls with no treatment
169.5 ± 11.2 pg/ml (p<0.001). CA IX levels in the prednisolone
group were almost comparable to the baseline levels (sham)
112.6  ±  9.3  (n.s.)  (Figure  3,  A).  This  observation  correlated
also with the wet-to-dry ratios (Figure 2 C). As expression of
HIF-1  activation  upon  ischemia,  post-operative  VEGF-A
expression directly correlated with reperfusion edema. VEGF-A
mRNA  was  significantly  blunted  in  prednisolone-treated
animals 56.5 ± 1.7 and shams 67.9 ± 12.8 (expressed as % of
the  expression  of  the  Perfadex  group)  compared  to  controls
104.3  ±  10.2%  (p<0.05).  Tissue  VEGF-A  protein  expression
was  significantly  upregulated  in  Perfadex-treated  animals
(3251  ±  50.32  mean  pixel  density)  vs.  sham  (2034  ±  50.32
mean  pixel  density;  P<0.01).  Prednisolone  treatment  could
significantly lower these expression levels even below normal
values  (1559  96.76  mean  pixel  density;  P<0.05).  Circulating
VEGF-A  detected  in  serum  samples  showed  a  significant
upregulation  of  VEGF-A  in  controls  181.4  ±  11.8  pg/ml  vs.
shams 145.6 ± 7.9 pg/ml as well as in animals that received
prednisolone 149.2 ± 2.3 pg/ml (p<0.05, Figure 3 B).
Neutrophil recruitment is increased in lungs treated
with Perfadex only and prednisolone treatment
decreases neutrophil invasiveness
Rats  receiving  lungs  that  had  been  treated  with  Perfadex
only  had  significantly  more  neutrophil  cells  46.88  ±  2.47
compared  to  prednisolone  treated  5.12  ±  0.74  or  sham  lung
cells 5.25 ± 1.04 (P<0.001, Figure 4 A). Prednisolone protects
from  hypoxia-induced  inflammation  by  downregulating  tissue
expression  of  specific  neutrophil  chemoattractants  such  as
CINC-1 (854.0 ± 74.43 mean pixel density), CINC-2α/β (283.5
± 38.40 mean pixel density) and LIX (1300 ± 54.64 mean pixel
density) vs. Perfadex (2134 ± 99.54, P<0.01; 621.5 ± 28.82,
P<0.01  resp.  2309  ±  80.91,  P<0.01  mean  pixel  density).
Regarding LIX expression, prednisolone (1300 ± 54.64 mean
pixel density) treatment resulted in lower levels compared to
sham  (2379  ±  28.8  mean  pixel  density,  P<0.01)  animals
(Figure 4 B). Neutrophil invasiveness, which was quantified by
MMP-2,  was  significantly  lower  in  prednisolone-pretreated
lungs  than  in  Perfadex  (101.9  ±  31.92%)  treated  ones
(P<0.01). However, levels in prednisolone-treated lungs (25.38
± 4.61%) were still significantly higher than in sham animals
(3.37 ± 0.50%; P<0.001, Figure 4C). In contrast, the natural
inhibitor  of  MMP-2,  TIMP-1,  was  significantly  upregulated  in
prednisolone-pretreated  (4642  ±  57.36,  mean  pixel  density)
lungs  compared  to  Perfadex  (3285  ±  37.44,  mean  pixel
density) treated lungs, whereas both interventional groups had
significantly higher levels compared to sham (593.4 ± 46.56,
mean pixel density) animals (P<0.001, Figure 4C).
Prednisolone influences the lung macrophage
composition in the reperfusion phase
Prednisolone-treated  animals  had  high  gene  expression
levels  of  MMP-12  (macrophage  MMP)  105.7  ±  40.0%  when
compared  to  shams  0.21  ±  0.09%  (P<0.05),  which
corresponded  to  the  MMP-12  expression  of  control  animals
124.9  ±  38.0%.  When  directly  counting  the  amount  of
macrophages in micrographs, we observed that prednisolone-
Prednisolone and Macrophage Polarization
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e73298Figure 2.  Prednisolone preserves the macro- and microstructural aspect of the grafts and reduces reperfusion edema
formation following LTX.  (A) Image shows explanted lungs 48 hours after LTX. Lungs from prednisolone-treated animals (right
picture), Perfadex-treated lungs (middle picture) and sham lungs (left picture) were compared. L = left lobe, R = right lobe. (B)
Representative micrographs (H&E staining) showing microstructural alterations and alveolar thickening as edema surrogate by
directly comparing shams (left micrographs) with Perfadex-treated animals (middle) and prednisolone-preconditioned lungs (right
pictures). (C) Quantification of the alveolar thickening by measuring the percentage of tissue occupying every slide (ratio tissue vs.
no tissue, left graph). Values are expressed as % tissue/slide (n=3 random slides per animal). Quantification of the amount of
edema (lung water) by evaluating the wet-to-dry ratio (right graph), n=6 per group. Calibration bar for macroscopic pictures (A)
represents 1 cm. Calibration bar for H&E micrographs (B) represents 100 µm (200 x magnification, upper micrograph) and 50 µm
(400 x magnification, lower micrograph). Significance level was set to P<0.05. P<0.05: *; P<0.01: **, § § and P<0.001: ***. * =
significantly different from shams and § = significantly different from Perfadex-group. ANOVA followed by Bonferroni’s post-hoc
multiple comparisons test.
doi: 10.1371/journal.pone.0073298.g002
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PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e73298Figure 3.  Prednisolone reduces hypoxia induced signaling and attenuates VEGF-A expression.  . (A) Circulating carbonic
anhydrase (CA) IX has been measured by ELISA in serum samples of all animals (values are expressed in pg/ml). (B) VEGF-A
expression (mRNA, circulating and tissue protein) have been detected by RT-PCR (upper left graph, values expressed as % of
Perfadex groups, Perfadex group has been set at 100%), ELISA (upper right graph, expression in pg/ml) and protein array (lower
left graph, values expressed in mean pixel densities). Significance level was set to P<0.05. P<0.05: *, § and P<0.01: **, § § and
P<0.001: § § §. * = significantly different from shams and § = significantly different from Perfadex-group. RT-PCR: experiments were
performed in triplicate, protein array: pooled analysis in duplicate. ANOVA followed by Bonferroni’s post-hoc multiple comparisons
test.
doi: 10.1371/journal.pone.0073298.g003
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PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e73298Figure 4.  Prednisolone inhibits neutrophil invasion after LTX.  (A) Specific neutrophil staining (arrows, micrographs) and
quantification (left graph). Data are expressed as number of neutrophils/field. (B) Measurement of tissue protein expression of
neutrophil chemoattractants in transplanted lungs by protein array. Data are expressed in mean pixel densities. (C) Evaluation of
MMP-2 mRNA expression (measured by RT-PCR, data are expressed as % of Perfadex group, Perfadex group has been set at
100%) and its Inhibitor TIMP-1 by protein analysis (protein array). (D) Representative protein array pictures. Calibration bar for
micrographs (A) represents 100 µm (200 x magnification, upper micrographs) and 50 µm (400 x magnification, lower micrographs).
Significance level was set to P<0.05. P<0.01: **, § § and P<0.001: § § §. * = significantly different from shams and § = significantly
different  from  Perfadex-group.  RT-PCR:  experiments  were  performed  in  triplicate,  protein  array:  pooled  analysis  in  duplicate.
ANOVA followed by Bonferroni’s post-hoc multiple comparisons test.
doi: 10.1371/journal.pone.0073298.g004
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the corresponding controls (67.4 ± 1.9 cells; P<0.01). However,
their  number  was  significantly  increased  in  both  control  and
prednisolone groups when compared to shams (7.7 ± 1.1 cells;
P<0.001; Figure 5A).
We observed that animals receiving prednisolone had much
higher amounts of CD68+ cells/field (61.3 ± 3.5 cells) than the
corresponding Perfadex-treated (19.7 ± 1.5 cells; P<0.001) or
sham  rats  (8.5  ±  2.2  cells;  P<0.001).  Perfadex-treated  lungs
had significantly more CD68+ cells than the shams (P<0.05).
The  amount  of  CD68+  cells  corresponded  to  the  amount  of
total macrophages in the prednisolone group. A high number of
CD68+ stained cells were found in prednisolone treated lung
grafts,  however  their  number  was  even  higher  in  regions  of
atelectasis (Figure 5B).
Prednisolone-pretreatment decreases ICAM-1 related
pro-inflammatory cell activation
By measuring ICAM-1 tissue mRNA expression, the state of
activation  of  inflammation  related-cells  was  evaluated.  We
found, that only in rats receiving prednisolone perfused lungs
(133.3 ± 37.6%), ICAM-1 mRNA was significantly upregulated
vs. sham (32.4 ± 6.8%; P<0.01) whereas ICAM-1 mRNA was
also  higher  in  Perfadex-treated  lungs  (100.0  ±  38.83%)
however this was not significant. In micrographs, the absolute
number  of  ICAM-1  positive  cells  was  significantly  higher  in
controls (63.3 ± 6.3 cells) compared to prednisolone (44.4 ± 3.2
cells; P<0.01) or sham animals (6.1 ± 1.2 cells; P<0.001). In all
animals  that  underwent  a  transplantation  procedure  (with  or
without prednisolone), ICAM-1 positive cells were significantly
increased (P<0.001) compared to shams (Figure 6 A).
Immunofluorescence  analysis  of  lung  tissue  revealed  that
prednisolone-pretreated  lungs  mainly  contained  ICAM-1
positive macrophages, whereas in Perfadex only-treated lungs,
ICAM-1  was  originating  in  large  parts  from  other  cells  than
macrophages  (Figure  6B,  red:  macrophages,  green:  ICAM-1
positive cells, purple: ICAM-1 positive macrophages).
The  gene  expression  of  the  pro-inflammatory  CXCR4  was
significantly  upregulated  in  controls  (91.1  ±  16.8%)  when
compared  to  sham  (19.3  ±  4.9%;  P<0.001)  or  prednisolone
treated  animals  (33.9  ±  9.9%;  P<0.01).  Simultaneously,
CXCR4  protein  expression  was  significantly  lower  after
prednisolone treatment (44.5 ± 2.0%) when compared to the
corresponding controls (100.0 ± 10.2%; P<0.01). Concordantly
with  these  observations,  sham  (5.00  ±  0.40  cells)  and
prednisolone-treated (5.29 ± 0.39 cells) lungs had significantly
less CXCR4 positive cells, compared to Perfadex-treated lungs
(7.96 ± 0.68 cells; P<0.05; Figure 6C).
Prednisolone orchestrates the microenvironmental
inflammatory response by inhibition of pro- and
activation of anti-inflammatory pathways
Tissue protein expression of tumor necrosis factor (TNF)-α
was significantly upregulated in Perfadex-treated lungs (362.0
± 24.42 mean pixel density) when compared to prednisolone-
treated animals (202.5 ± 15.75 mean pixel density) or shams
(192.2  ±  14.94  mean  pixel  density;  P<0.05).  Tissue  protein
expression of chemokine (C-X-C motif) ligand (CXCL) 7 was
significantly  upregulated  in  Perfadex-treated  lungs  (4025  ±
163.0  mean  pixel  density)  when  compared  to  prednisolone-
treated animals (2794 ± 178.5 mean pixel density; P<0.05) or
shams  (2192  ±  63.88  mean  pixel  density;  P<0.01).  Tissue
protein  expression  of  macrophage  inflammatory  protein
(MIP)-1α  was  significantly  upregulated  in  Perfadex-treated
lungs (898.0 ± 49.28 mean pixel density) when compared to
prednisolone-treated  animals  (528.0  ±  16.41  mean  pixel
density; P<0.05) or shams (321 ± 19.35 mean pixel density;
P<0.01).  Tissue  protein  expression  of  interleukin-1  receptor
antagonist  (IL-1ra)  was  significantly  downregulated  in
Perfadex-treated lungs (993.6 ± 0.44 mean pixel density) when
compared to prednisolone-treated animals (3582 ± 108.4 mean
pixel  density;  P<0.01)  or  shams  (2972  ±  161.1  mean  pixel
density;  P<0.01).  Tissue  protein  expression  of  regulated  on
activation,  normal  T  cell  expressed  and  secreted  (RANTES)
was  significantly  downregulated  in  Perfadex-treated  lungs
(1527 ± 149.0 mean pixel density) compared to prednisolone-
treated animals (2950 ± 139.0 mean pixel density; P<0.05) but
not to shams (2248 ± 234.8 mean pixel density; n.s.). Finally,
tissue  protein  expression  of  the  anti-inflammatory  IL-4  was
significantly upregulated in prednisolone-treated lungs (2672 ±
96.09 mean pixel density) when compared to Perfadex-treated
animals (923.1 ± 50.30 mean pixel density; P<0.001) or shams
(662.1 ± 11.89 mean pixel density; P<0.001) (Figure 7A).
Prednisolone enhances transdifferentiation of
macrophages towards the anti-inflammatory M2
phenotype
Additional gene expression analysis of IL-13 revealed that its
mRNA  expression  was  significantly  upregulated  in
prednisolone  (583.8  ±  192.8%)  vs.  control  (100.0  ±  33.5%;
P<0.01) or sham animals (2.3 ± 0.4%; P<0.01).
Simultaneously the mannose receptor C type (MRC)-1 gene
expression  was  significantly  upregulated  in  prednisolone
animals (243.6 ± 31.5%) compared to controls (100.0 ± 24.9%;
P<0.001) or shams (35.8 ± 11.9%; P<0.001) indicating a M2
transdifferentiation in the prednisolone treated rats (Figure 8A).
M2 macrophages mostly express high levels of CD163. By
counting CD163+ cells we observed a significantly increased
number in prednisolone treated animals (27.5 ± 2.5 cells) vs.
controls (8.2 ± 2.8 cells; P<0.001) or shams (4.1 ± 0.6 cells;
P<0.001; Figure 8B).
Discussion
Ischemia and reperfusion injury (IRI) represents one of the
main causes of early graft dysfunction and poor outcome after
transplantation [5,6,42,43]. IRI is often accompanied by tissue
damage  resulting  in  edema  and  with  increased  inflammatory
cell invasion into the graft [44]. Corticoids have been used for
decades  to  treat  inflammatory  disorders  especially  in
transplantation  medicine  [45],  where  they  are  usually
administered  immediately  before  antigen  contact  or  during
manifest inflammation episodes i.e. during acute rejection. The
approach  that  corticosteroids  are  administered  via  the
perfusion solution to prevent damage from induced by ischemia
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PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e73298Figure 5.  Prednisolone has no direct effect on the number of macrophages invading the grafts after LTX.  (A) Quantification
of the total number of macrophages per field. Total macrophage staining was performed by immunohistochemistry (micrographs)
and macrophage counting was performed (left upper graph). The macrophage specific MMP-12 gene expression was quantified by
RT-PCR  (left  lower  graph).  (B)  Quantification  of  CD68  positive  cells.  CD68+  cells  have  specifically  been  stained  for
immunohistochemistry (right micrographs) and positively stained cells per field (brown) have been counted (left graph). Calibration
bar  for  micrographs  represents  100  µm  (200  x  magnification,  upper  micrographs)  and  20  µm  (1000  x  magnification,  lower
micrographs). N=3 fields per slide have been evaluated. Significance level was set to P<0.05. P<0.05: *, P<0.01: **, § § and
P<0.001: § § §. * = significantly different from shams and § = significantly different from Perfadex-group. RT-PCR: experiment was
performed in triplicates and data are expressed as % of Perfadex group (Perfadex group has been set at 100%), protein array:
pooled analysis in duplicate. ANOVA followed by Bonferroni’s post-hoc multiple comparisons test.
doi: 10.1371/journal.pone.0073298.g005
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PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e73298Figure  6.    Prednisolone-pretreatment  decreases  ICAM-1  related  pro-inflammatory  cell  activation.    (A)  The  cellular
inflammation activation marker ICAM-1 was assessed by gene expression analysis using RT-PCR (left graph) and specific ICAM-1
staining (micrographs, arrows) and counting of the ICAM-1+ cells per field (right graph). A subdivision for low ICAM-1 positive cells
(micrographs, encircled areas) was performed. (B) Representative immunofluorescence triple staining pictures on ICAM-1 (green),
macrophages (RM-4, red) and cell-cores (DAPI, blue). ICAM-1 and RM-4 co-expressing cells are colored in purple. Calibration bar
represents 20 µm. (C) CXCR4 expression analysis was performed by immunohistochemistry (micrographs), mRNA expression
analysis  by  RT-PCR  (upper  right  graph)  and  western  blot  analysis  (lower  graph,  representative  western  blots  (right  picture)).
Calibration bar represents 100 µm (200 x magnification, CXCR4 stainings), 50 µm (400 x magnification, upper ICAM stainings)
respectively 20 µm (1000 x magnification, lower ICAM stainings). N=3 fields per slide have been evaluated. Significance level was
set to P<0.05. P<0.05: *, P<0.01: **, § § and P<0.001: § § §. * = significantly different from shams and § = significantly different from
Perfadex-group. RT-PCR and western blot analysis experiments were performed in triplicates and data are expressed as % of
Perfadex group (Perfadex group has been set at 100%). For CXCR4 staining, data are expressed as the ratios of CXCR4 positive
vs. CXCR4 negative areas per field. ANOVA followed by Bonferroni’s post-hoc multiple comparisons test.
doi: 10.1371/journal.pone.0073298.g006
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PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e73298Figure 7.  Prednisolone induces M2 macrophage polarization.  (A) The gene expressions of the anti-inflammatory cytokine
IL-13 and of a marker for M2 polarization, MRC-1, were analyzed by RT-PCR. (B) Selective immunohistochemical CD163 staining
(brown cells) and counting of the cells (graph). N=3 fields per rat have been evaluated. Significance level was set to P<0.05.
P<0.01: **, § § and P<0.001: § § §. * = significantly different from shams and § = significantly different from Perfadex-group. RT-
PCR experiments were performed in triplicates and means are expressed as % of Perfadex group (Perfadex group has been set at
100%). ANOVA followed by Bonferroni’s post-hoc multiple comparisons test.
doi: 10.1371/journal.pone.0073298.g007
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unclear.
In the present work we show that prednisolone, administered
in combination with the perfusion solution during the phase of
graft ischemia, is protective, significantly improves short-term
survival  and  attenuates  reperfusion  injury  in  a  rat  model  of
orthotopic LTX. Animals that showed an inflammatory reaction
in the reperfusion phase died of global pulmonary edema. In
fact,  we  observed  inflammation  occurring  in  the  transplanted
lung  also  affected  the  right  (not  transplanted)  lung,  an
observation that is not new but that has often been neglected
[46]. This observation impressively shows that IRI is not only a
local process but rather a systemic one.
Moreover,  we  could  show  in  our  orthotopic  transplantation
model  that  it  makes  sense  to  treat  ischemia  related  effects
already prophylactically at the stage of organ procurement. Our
Figure 8.  Prednisolone induces anti-inflammatory and inhibits pro-inflammatory pathways.  (A) Tissue protein expression of
TNF-α, CXCL7, MIP-1α, IL-1ra, RANTES and IL-4 were evaluated using protein arrays. Experiments using pooled samples from
n=6 rats per group were performed in duplicates. (B) representative array pictures. Significance level was set to P<0.05. P<0.05: *,
§; P<0.01: **, § § and P<0.001: § § §. * = significantly different from shams and § = significantly different from Perfadex-group Data
are expressed as mean pixel densities. ANOVA followed by Bonferroni’s post-hoc multiple comparisons test.
doi: 10.1371/journal.pone.0073298.g008
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ischemia  driven  pathways  such  as  HIF-1,  a  pathway  that  is
known to strongly induce inflammation, edema (via VEGF) and
organ  damage  [4,8,22,47].  However,  the  influence  of
prednisolone on the HIF pathway might not be strong enough,
as seen in VEGF-A analysis. However the VEGF-A production
is significantly blunted in prednisolone-treated lungs, it is even
below  values  recorded  in  sham  animals.  The  extent  of  the
edema still remains higher in the prednisolone group compared
to shams (Figures 2 and 3). Nevertheless, prednisolone does
not only act as anti-edematous substance, its anti-inflammatory
immune  modulatory  properties  might  be  the  most  important
actions of prednisolone. In an earlier work, we could already
show, that protein biosynthesis is not completely blunted under
cold  ischemia  [4].  This  is  important  to  know,  as  pro-
inflammatory mechanisms can already be activated during the
phase of conservation. On the other hand this also means that
pharmacological  anti-inflammatory  intervention  might  also  be
effective  at  this  stage  and  thus  prevent  deleterious  effects
when  reperfusion  commences.  Inflammatory  cell  invasion
might  represent  the  most  important  point  of  action  as
neutrophils and macrophages are among the first line of attack
during  reperfusion  and  might  amplify  the  inflammatory
response and thus the graft injury (Figures 4-6). While our data
clearly supports such a function, it has to be mentioned that our
findings represent only a snapshot at a certain point of time.
The  fact  that  the  post-inflammatory  process  is  very  dynamic
can be observed in IFN-γ, IL-6 and IL-10 expression (Figure
S1).  These  classical  inflammation-modulating  factors  are
known to play a role during almost every inflammatory process.
However in our model they seem to play a minor role or might
even play an opposite role to the one known from literature.
IL-10  has  been  described  as  anti-inflammatory  and  being
involved in anti-inflammatory M2 macrophage polarization [32].
However, in our model, IL-10 mRNA expression is upregulated
in  the  Perfadex  as  well  as  in  the  prednisolone  group  and
additionally its protein expression is significantly higher in the
prednisolone group. The latter observation correlates with the
anti-inflammatory  properties  of  IL-10.  We  assume,  that  the
mRNA  upregulation  of  IL-10  in  the  Perfadex  group  might
represent  a  naturally  occurring  counter-mechanism  to  limit
inflammation and that this mechanism might be accelerated by
prednisolone. In the present model, at least IL-4, IL-13, IL-1ra
and RANTES, known molecules described to be involved in M2
polarization in previous studies, seem to have a central role in
mediating the action of prednisolone into an anti-inflammatory
response [26–28]. This may thus explain the reason why the
amount of macrophages in the prednisolone group is similar to
the Perfadex group. There might be a phenotypical difference
between  those  two  populations,  indicating  that  the
macrophages  from  the  prednisolone  group  are  anti-
inflammatory  ones.  This  is  supported  by  the  CD163  and
MRC-1  data  (Figure  8).  Additionally,  immunofluorescence
pictures show, that in the Perfadex group the inflammation is
mainly  mediated  via  ICAM-1  positive  cells,  whereas  this
observation is missing in the prednisolone group. Whether the
M2 macrophages are newly recruited or whether they derive
from  resident  macrophages  remains  unclear  at  present  and
might be a subject for further investigations.
Taken  together,  we  have  shown  that  the  application  of
prednisolone already in the early phase of organ procurement
has a beneficial outcome. Importantly, this substance is well
characterized  and  has  an  acceptable  good  safety  profile
[48,49], making it an attractive candidate for the use in human
transplantations.
Materials and Methods
Ethics statement
The  study  was  approved  by  the  Animal  Care  and  Use
Committee  of  the  state  of  Hessen  (Regierungspräsidium
Darmstadt),  Germany  (V54-19c20/15-F91/56).  Surgery  and
animal care was performed in accordance with the „Guide for
the care and use of laboratory animals“ (National Institutes of
Health, volume 25, no. 28, revised 1996), EU Directive 86/609
EEC and German Protection of Animals Act.
Animals
Male  Sprague  Dawley  rats  (Janvier,  France)  weighing
225-250g  were  housed  in  the  central  research  facility  of  the
Goethe-University  Frankfurt.  At  the  beginning,  rats  were
randomized  to  form  pairs  of  donor  and  recipient  rats,  which
were kept together in approved plastic cages (2 animals per
cage). Animals were provided with water and food ad libitum.
Housing rooms were equipped with a 12 h light cycle.
Lung transplantation
Lung  transplantation  was  performed  as  described  in  detail
elsewhere [4]. In short, transplantations were carried out iso-
allogenically from Sprague Dawley to Sprague Dawley to avoid
any kind of rejection reaction. For each of the groups surgery
was  performed  until  n=6  recipients  survived.  For  organ
preservation, 20 ml ice-cold low potassium standard dextrane
containing perfusion solution Perfadex (Vitrolife, Sweden) was
used to perfuse the heart lung package of the donors. Perfadex
is used to quickly cool down und thus preserve lungs used for
transplantation. In the prednisolone group 100 mg prednisolone
was added to the perfusion solution. The dose of 100 mg was
based on preliminary experiments. Briefly, for evaluation of the
lung’s  intravascular  volume,  organs  were  perfused  with
Perfadex  substituted  with  Evans  blue.  Before  perfusion,  the
total  weight  of  the  perfusion  solution  was  determined.
Antegrade perfusion was performed in n=4 rats by insertion of
a venous catheter through the right ventricle directly into the
pulmonary artery (Figure S2, A). Perfusion was carried out until
Evans  blue  was  visibly  flowing  out  of  the  left  atrial  auricle
(Figure  S2,  B).  To  verify  the  efficient  perfusion,  the  lung
package  had  to  turn  blue  after  perfusion  with  Evans  blue
(Figure S2, C). The remaining solution was weighed and the
difference  was  calculated.  Using  the  specific  weight  of
Perfadex  (1015,5  g/l),  we  were  able  to  calculate  the  mean
pulmonary  vascular  volume.  As  the  mass  oft  he  left  lung  is
about 1/3 of the mass of the whole lung package, the mean left
lung intravascular volume could be calculated to be 545 µl. By
Prednisolone and Macrophage Polarization
PLOS ONE | www.plosone.org 12 August 2013 | Volume 8 | Issue 8 | e73298using 100 mg/20 ml Perfadex for perfusion, the calculated dose
per  rat  was  then  3  mg/250(g/rat)  =  12  mg/kg.  This  dose  is
similar to the initiation dose used in humans to induce immune
tolerance at reperfusion ranging from 6–15 mg/kg prednisolone
[50–52]. The controls were perfused with Perfadex alone and
did not receive prednisolone as additive. Sham animals were
only subjected to a thoracotomy. Total ischemia time was set at
1h, where 45 minutes where accounted to cold ischemia and
10-15  minutes  (according  to  the  pace  of  the  transplantation
procedure) to warm ischemia. Reperfusion was only initiated
after 1h total ischemia time.
Pain management was ensured with intercostal injection of
600  µl  ropivacaine  (0.2%)  and  with  piritramid  added  to  the
drinking water (4.5 mg/200 ml). The recipients were observed
for additional 48 h and then sacrificed under deep anesthesia.
Lungs were harvested, dissected and stored at -80° or were
formalin fixed (4%) and embedded in paraffin for later use [4].
Wet-to-dry ratio
A small part of the collected lungs was minced and stored in
a reaction tube and the weight determined. Then the tube was
placed into an oven at 60°C for 72h. Following this, the tube
was re-weighed, the weight of the tube was subtracted and the
ratio between wet and dry weight was calculated [4,53].
RNA isolation and PCR
RNA  isolation  and  reverse  transcription  was  performed  as
described elsewhere [4]. Realtime-PCR was performed using
the StepOne Plus device (Applied Biosystems, USA). For rat
specific primer sequences, see Table 1.
Protein isolation, Western Blot, ELISA and protein
arrays
Proteins  were  isolated  according  to  a  standard  protocol
[4,54,55]. 10 % and 7.5 % SDS-gels were loaded with 50 µg
protein. Proteins were detected on Hybond C supermembrane
(Amersham Pharmacia Biotech, UK) with Spectra brood range
marker (Fermentas, Germany) as a standard. The blots were
probed with antibodies against: CXCR4 (Abcam, UK), VEGF
(Abcam,  UK)  and  β-Actin  (Abcam,  UK).  Digitalization  and
evaluation  of  the  blots  was  performed  with  a  Kodak  Imager
Table 1. Rat specific primer sequences.
  forward reverse
CXCR4 CACCAACAGCCAGAGCGCGA TGCGCTTCTGGTGGCCCTTG
VEGF-A CCAGGCTGCACCCACGACAG CGCACACCGCCATTAGGGGCA
ICAM-1 CGCAGTCCTCGGCTTCTGCC CGCAGTCCTCGGCTTCTGCC
β-Actin CTTGCAGCTCCTCCGTCGCC CTTGCTCTGGGCCTCGTCGC
CD 163 TGGGATCGCCGTGACGCTTC CAGCGACTGCCTCCACCGAC
IL-4 GGCTTCCAGGGTGCTTCGCAA GTGGACTCATTCACGGTGCAGC
IL-13 GTGGTCTTGCCACCCCAGGG CGCCAGCTGTCAGGTCCACG
MRC-1 ACGGGTGACCCTTCGGGTGA GCCGCAACACCGGCACCTAT
MMP-2 CAAGTTCCCCGGCGATGTC TTCTGGTCAAGGTCACCTGTC
MMP-12 TTGGCCATTCCTTGGGGCTGC TGTTGGTGGCTGGACTCCCAGG
doi: 10.1371/journal.pone.0073298.t001
(Carestream,  Germany).  For  serum  sampling,  blood  was
withdrawn and clotting was performed for 15 minutes followed
by centrifugation at 3.000 RPM for 10 minutes at 4°C. Serum
supernatant was used for ELISA on rat carbonic anhydrase IX
(Hölzel  Diagnostika,  Germany),  rat  VEGF-A  (R&D  Systems,
Germany),  rat  IFNγ  and  rat  IL-6  (Thermo,  Fisher,  Germany)
which  were  performed  according  to  the  manufacturer’s
protocol.  For  rat  cytokine  array  (Proteome  Profiler,  R&D
systems,  Germany)  whole  lung  protein  lysates  were  pooled
from  each  group  in  equal  amounts  to  obtain  300  µg  protein
solution for each group. Membranes were then incubated and
developed according to the manufacturer’s protocol. Detection
of  the  luminescence  was  performed  with  Kodak-Imager
(Carestream, Germany).
Histology immunohistochemistry and
immunofluorescence
Preparation  of  paraffin  embedded  samples  was  performed
as described elsewhere [4]. Samples were stained with H&E
(AppliChem,  Germany)  according  to  the  manufacturer’s
protocol.  Immunohistochemistry  was  performed  by  using  CD
163  (AbD  Serotec,  Germany),  CD  68  (Millipore,  Germany),
ICAM-1 (Labomics, Belgium), RM-4 pan-macrophage/dendritic
cell  marker  (TransGenic  Inc.,  Kobe,  Japan)  and  CXCR4
(Abcam,  UK)  antibodies  [4].  For  detection,  corresponding
secondary  antibodies  labelled  with  biotin  were  used  prior  to
detection  with  streptavidin-HRP  (AXXORA,  Germany).
Development  was  performed  with  DAB  and  counterstaining
was done with haematoxylin. For immunofluorescence we used
mouse  monoclonal  anti  rat  macrophage/dendritic  cells  RM4
(TransGenic Inc., Kobe, Japan) and the rabbit polyclonal anti
CD54/ICAM-1  (Biozol  Diagnostica,  Germany).  Detection  was
performed by incubating the slides with secondary anti-mouse
PE (eBioscience, USA) conjugated and anti rabbit Alexa Fluor®
488  (Molecular  Biotechnology,  Germany)  conjugated
antibodies.  Core  staining  was  carried  out  with  DAPI  (Vector
Laboratories,  USA)  staining.  Pictures  were  taken  for  every
fluorescent  dye  and  images  were  merged  to  show  co-
expression of ICAM-1 and RM4.
Histological  examinations  were  conducted  in  a  blinded
fashion. Three slides per animal were stained. Pictures were
then  taken  from  the  same  lung  area  (peripheral  longitudinal
section) and 3 fields per slide were photographed randomly.
Evaluation  of  the  edema  was  performed  by  analyzing  the
amount of tissue (colored area) vs. no tissue (uncolored area)
per  field.  The  algorithm  calculated  the  amount  of  pixel  that
were covered by the stained tissue in the respective pictures
and calculated the amount of pixel of the uncolored area and
expressed the values as % of the total pixel. We define colored
pixel as being a part of tissue, concluding that all stained areas
are covered with tissue. This technique was already validated
elsewhere and showed high accuracy [4]. Images were taken
with the Leica DM5000B microscope, stored in tagged image
file  format  and  analyzed  using  an  automatized  Matlab  script
(The  Mathworks,  USA)  programmed  by  the  authors.  The
routine determines the color-values of pixels in the red-green-
blue space (RGB), thus measuring the relative area occupied
by blue, red and green staining per image. Quantification was
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of all pixels and the number of uncolored pixels. As internal
negative  control,  isotype  IgG  stainings  were  performed
(pictures not shown).
Statistical analysis
Statistical  analysis  was  performed  with  GraphPad  Prism®
5.02  software  (GraphPad  Software,  Inc.,  California,  USA).
Results are expressed as means ± standard error of the mean
(SEM).  Statistical  significance  was  calculated  using  ANOVA
followed  by  a  post  hoc  analysis  using  Bonferroni’s  multiple
comparison tests. Statistical significance was set to p< 0.05 (*
p<0.05, ** p<0.01, *** p<0.001).
Supporting Information
Figure S1.  Expression of IFN-γ, IL-6 and IL-10 following
LTX. (A) Circulating levels of IFN-γ were detected using ELISA
(left graph). Tissue protein expression of IFN-γ was measured
using a protein array middle graph. Exemplary pictures of the
profiler for IFN-γ are shown on the right. (B) Circulating IL-6
levels were detected using ELISA (left graph). Tissue protein
expression of IL-6 was measured using a protein array middle
graph. Exemplary pictures of the profiler for IL-6 are shown on
the right. (C) IL-10 gene expression was assessed by RT-PCR
analysis  (left  graph).  Tissue  protein  expression  of  IL-10  was
measured  using  a  protein  array  middle  graph.  Exemplary
pictures  of  the  profiler  for  IL-6  are  shown  on  the  right.
Significance level was set to P<0.05. P<0.05: *, §, P<0.01: **
and P<0.001: ***. * = significantly different from shams and § =
significantly  different  from  Perfadex-group.  RT-PCR
experiments  were  performed  in  triplicates  and  data  are
expressed as % of Perfadex group (Perfadex group has been
set  at  100%),  protein  array:  pooled  analysis  in  duplicate.
ANOVA  followed  by  Bonferroni’s  post-hoc  multiple
comparisons test.
(TIFF)
Figure S2.  Prednisolone dose finding pilot experiment. (A)
Insertion  of  the  perfusion  catheter  through  an  incision  in  the
right ventricle directly into the pulmonary artery (*). (B) Begin of
the perfusion procedure with Perfadex substituted with Evans
blue (n=4 rats). Perfusion was stopped at the moment where
the blue color was flowing out of the left atrial auricle (arrow).
(C) At the end of the perfusion, the lungs turned completely
blue as proof of efficient perfusion. The remaining volume of
perfusion  solution  was  determined  and  the  difference  was
calculated.  After  determination  of  the  left  and  right  lung
weights,  the  corresponding  final  left  and  right  lung  volumes
could be extrapolated.
(TIFF)
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